TScan Therapeutics (TCRX)

• Market cap: $64.7M
• 1 day: 1.79%
• 5 days: -40.93%
• 1 month: -44.39%
• 3 months: -34.86%
• 6 months: -24%
• Year to date: -63.11%
• 1 year: -78.45%
• 5 years: -89.14%
• 10 years: -89.14%
• Sector: Healthcare
• Industry: Biotechnology

About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 210